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The Clock is Ticking: It's Time
to END TB
World TB day is observed on 24th of March
every year. This year’s theme is “The Clock
is Ticking”. This day is designed to raise
public awareness about the TB epidemic,
which is still the number one killer
globally among infectious diseases.
Tuberculosis is a curable and preventable
disease. The global burden of the disease
attributes to delay and poor diagnostic
and inadequate treatments, which leads to
the severity of the disease with an
increase in mortality rate and the spike in
transmission and development of drug
resistance. TB does not spare any country
in the world, even though it unreasonably
impacts LMIC (lower- to middle-income
countries). A total of 3% of global TB
cases occur in the WHO European Region.
In the US, about 13 million people live with
latent TB.
Dr. Nibedita Rath, Scientific Director,
Open Source Pharma Foundation,
Bangalore
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If we look at the response and aggressiveness
the world has laid down to address the Covid-
19 pandemic, the same show has not been put
up for TB even though it is a century-old
problem globally. Both Covid-19 and TB has
the capacity to stress healthcare systems. The
current pandemic has seen rapid diagnosis
and public awareness for disease control and
containment, whereas insufficient and
inadequate diagnostics in Tuberculosis keeps
fuelling the on-going disease transmission in
many settings. The critical ingredients of
infectious disease control are creating an
ecosystem of trained healthcare workers in
recognizing the disease and an effective
surveillance system to monitor the behaviour.
This requires a tremendous effort from the
regional and central level and must be backed
by financial and human resources.
Tuberculosis at large has never seen a data
and knowledge sharing platform that Covid-
19 has witnessed. The lack of coordination
and sharing of information and data at the
national and international level has created
barriers to informative datasets that could
have facilitated and accelerated quality
research in Tuberculosis. TB has seen a long-
standing paucity of funding to address
different issues associated with the disease
ranging from surveillance, reporting,
diagnosis, treatment, policy and research, to
name a few. The current pandemic will change
the future of vaccine discovery and
development. There is a paradigm shift in
vaccine technology. The accelerated speed at
which multiple vaccines have come up to
address the current pandemic is
overwhelming. It has shown when all the
resources are at their disposal how fast
vaccine development can proceed when there
is a global emergency. Can we imbibe this
learning for other neglected diseases such as
Tuberculosis?
There is a critical need for new TB vaccines
that are more effective than the Bacille
Calmette-Guérin (BCG) vaccine in preventing
pulmonary and extrapulmonary forms of TB in
all age groups. THE century-old BCG vaccine
is immunoprotective against extra pulmonary
paediatric TB, including meningitis. However,
the protection provided against pulmonary TB
in adults is variable. New vaccines are also
required keeping in view the slow decline in
TB incidence globally and the persistent
threat of MDR-TB. The article from Prof
Madhukar Pai in this issue is an eye-opener,
as he rightly said, “It’s time to use Covid-19
innovations and systems to reimagine TB
care”. The long duration of the current TB
treatment and side effects associated with it
leads to non-compliance, ultimately resulting
in MDR and XDR TB. There is a greater need
for developing a shorter regimen. Article by
Drs Shingar and Pawan Sharma has thrown
light on the current effort on shortening the
treatment duration from 6 months to 4
months as shown by a phase 3 clinical trial
study (Study 31/A5349). The study included
eight weeks of daily treatment with high-dose
rifapentine, isoniazid, pyrazinamide, and
moxifloxacin and nine weeks of daily
treatment with rifapentine, isoniazid, and
moxifloxacin. The treatment was well-
tolerated and found to be non-inferior in
efficacy to the standard six-month regimen
(2RHZE/4RH), which includes eight weeks of
daily treatment with rifampin, isoniazid,
pyrazinamide, and ethambutol and 18 weeks
of daily treatment with rifampin and isoniazid.
The world is overwhelmed by vaccine
development to address the current
pandemic. The article by Dr Saheed Jawahar
has reflected the current advancement in
vaccine development for Tuberculosis.
Countries with high levels of Tuberculosis 
 face   a   significant  comorbidity  burden 
 from
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It's Time To Use Covid-19
Innovations And Systems to
Reimagine TB Care
It's Time To Use Covid-19 Innovations And Systems to
Reimagine TB Care (forbes.com)
Even as the world comes to grips with the mounting
death toll due to the Covid-19 pandemic, the WHO
released its 2020 Global Tuberculosis Report last
week. The news is not good. Nearly 1.4 million people
died from TB in 2019. Of the estimated 10 million
people who developed TB that year, some 3 million
were either not diagnosed, or were not officially
reported to national authorities.
As expected, the Covid-19 pandemic is making things
worse, with 25-30% drops in TB notifications reported
in 3 high burden countries – India, Indonesia, the
Philippines – between January and June 2020 compared
to the same 6-month period in 2019. These reductions
in case notifications and ongoing disruptions to TB
services could substantially increase TB deaths.
Prof. Madhukar Pai, Canada Research Chair
in Translational Epidemiology & Global
Health, Associate Director, McGill
International TB Centre, Dept. of
Epidemiology, Biostatistics & Occupational
Health, McGill University
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both non-communicable and communicable diseases.
Prof M V Hosur article talks about the syndemic nature
of TB and HIV and how the mortality rate is three-fold
higher than just Mtb infection. Tuberculosis is not
restricted to human; it is seen in animal too. Dr
Rudrodip Majumdar article has emphasized
Tuberculosis in captive elephants, which has emerged
as a serious infectious zoonotic disease in the past few
decades.
The “Clock is Ticking”, and we need to put our act
together before it’s too late.
As I previous wrote, together, Covid-
19 and TB pose a deadly, dual threat
- a syndemic. Tremendous catch-up
work, advocacy, and funding is
needed, to get back on track, even
as the pandemic is pushing millions
of people into extreme poverty.
That cannot be good for TB, since
Poverty and TB are old pals. 
In the early days of the pandemic,
there was optimism that TB
technologies and systems could
help end the Covid-19 pandemic.
Indeed, molecular technologies
widely used for TB are being used to
test for Covid-19, and the BCG
vaccine for TB is being tested for
Covid-19. National TB program staff
(e.g. contact tracers) are engaged in
the Covid-19 response. TB wards
have been re-purposed to serve as
Covid-19 wards.
But now, given the massive
setback to progress in reaching
any of the TB targets, it’s time for
the TB community to ask: are there
Covid-19 innovations and systems
that can be effectively leveraged
to reimagine TB care? 
“In many low- and middle-income countries,
TB programs became the foundation of an
effective early response to Covid-19. Now,
as we are urgently rebuilding disrupted core
health services for TB and other conditions,
we have an opportunity to draw on the
toolbox of innovations that have been
created for Covid-19,” said Catharina
Boehme, CEO of FIND, Geneva. 
By speaking with a large number of experts,
I could indeed identify several opportunities
for the TB field (and vice-versa). 
Education, risk assessment & screening
Mobile apps & services (e.g. using
Whatsapp & chatbots) are being widely
used for public education on Covid-19, for
risk or self assessment, screening and
linkage to testing, for contact tracing and
mapping. 
For example, South Africa, building on its
success with Mom Connect, has reached
over 7 million people using a suite of digital
tools (e.g. COVID-19 Health Alert & COVID-19
Health Check). India’s open-source Aarogya
Setu mobile app has been downloaded by
over 150 million individuals. If these apps
can enhance TB contact tracing, that would
be a huge advance, since contact
investigation is an effective but underused
intervention in many high TB burden
countries.
According to Zameer Brey, a Senior Program
Officer at the Bill & Melinda Gates Foundation
in South Africa, these platforms and
technologies are being repurposed for TB.
"The 'disruptive' innovations that emerged
during the Covid-19 pandemic were waiting
beneath the surface to really enhance
patient-centered care across the most
vulnerable communities. The biggest tragedy
would be to quickly bury those innovations
and bury the hope of a more patient centric
system,” he said. 
Another way to screen for TB and Covid-19 is
to use digital chest x-rays (highly portable
systems now exist), with artificial-
intelligence (AI) solutions to make the
interpretation easier and less reliant on
expert radiologists. Such AI-based solutions
already exist, for TB as well as Covid-19. AI-
based algorithms can also identify CT scans
with COVID-19 associated pneumonia.
In South Africa, the National Department of
Health’s COVID-19 digital responses have
connected the ... [+] DEPARTMENT OF HEALTH,
SOUTH AFRICA
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Following long collaborative efforts, DOPASI,
Stop TB and Fujifilm launch TB screening of 400,
000 ... [+] DOPASI ORGANIZATION FOR
SUSTAINABLE DEVELOPMENT, PAKISTAN
“While TB needed AI interventions, the
development of such technologies was slow
because TB was (and still is) a poor person’s
disease. Covid-19 has not only ushered more
adoption for existing AI interventions, but
forced us to think what we can build beyond
usual offerings,” said Prashant Warier, CEO of
Qure.ai. “Initially, while a lot of TB solutions
were repurposed for Covid-19, now there is an
opportunity to reverse-purpose several
Covid-19 solutions for TB,” he added.
Automated recognition of cough duration and
sound patterns might help encourage care-
seeking and potentially screen for conditions such
as TB and Covid-19. Indeed, innovative R&D
around this is happening (e.g. Hyfe cough tracker
app). “How could the ability to detect and classify
coughs not be transformational?” asked Peter
Small, a TB expert and innovator at Global Health
Labs. 
Raghu Dharmaraju, a VP at Wadhwani AI is hopeful
about cough-based screening as well as greater
use of data science or pandemic response. “My
deepest hope is that we use this crisis to
accelerate the shift to truly data-driven health
systems,” he said. 
Innovative sample collection and diagnosis
“Innovative community-based (decentralized)
testing and enhanced case finding can be lessons
learned from Covid-19 and scaled up for TB,” said
Antonio Flores, a HIV/TB specialist with Médecins
Sans Frontières. 
Puneet Dewan, a physician and TB expert with
Global Health Labs agrees. “There has never been
so much enthusiasm and money in diagnostic
testing,” he says. He hopes some good can come
out of the current crisis. “We have to ensure we
end up with products and systems that meet TB
control needs,” he said. 
The demand for rapid and simpler Covid-19 testing
has pushed companies and health systems to
innovate around what samples to collect, where
to collect them, and how to make testing easier to
access. For example, samples such as saliva, rinse
and gargle, oral swabs, and even sampling of face
masks are being actively tried out. Better and
cheaper swabs have been developed (e.g.
polyester-based Q-tip-type swab).
Tremendous effort is being made to develop
home-based, self-tests for Covid-19. Mobile
testing sites, drive-through testing, and sample
collection via community health workers,
neighborhood pharmacies, schools and
workplaces are all happening.
Currently, TB testing is highly reliant on
sputum, a sample that is not easy to collect
and process. TB testing is also not easily
accessible at the primary care level. So, if
some of the innovative approaches around
Covid-19 sample collection & near-patient
access can be applied to TB, this might help
reduce the massive diagnostic gap in TB. 
“The unprecedented speed with which Covid-
19 tests have been developed is proof that
even technically challenging diagnostics can
become reality in record time,” says Morten
Ruhwald, Head of TB at FIND, Geneva. He
believes there is huge potential to expand
Covid-19 technologies across a spectrum of
respiratory diseases.
There are several rapid molecular diagnostic
platforms that are currently running Covid-19
and TB tests. Some of them are designed for
point-of-care use (e.g. GeneXpert and
TrueNat), while others are meant for high-
throughput, centralized laboratories (e.g. BD
Max, Abbott m2000, Roche Cobas). Wider use
of molecular technologies and bi-directional
testing can only be good for TB, and help the
field get rid of suboptimal tools such as smear
microscopy. 
In addition, great progress has been made
with rapid, point-of-care antigen testing for
Covid-19. Adapting this to develop simpler
POC tests for TB would be a massive advance.
. 
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A researcher from the Sys2Diag laboratory, from
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Rapid, high-sensitivity urine LAM
antigen detection technology holds
great promise and will benefit from all
the technology development around
Covid-19 rapid testing.
“Simple self-sampling (e.g. from face
masks) appears within reach – and in
combination with cutting-edge
molecular detection assays like CRISPR,
this could make at-home diagnosis of
respiratory infections not just as
straightforward as a pregnancy test, but
as accurate as conventional diagnostic
methods,” said Morten Ruhwald. 
“I am very enthusiastic about the
possibility of porting true point-of-care,
non-sputum based diagnostic systems
for use in TB. It's not just the
instrumented platforms, but non-
instrumented disposables that have
taken a flying leap forward,” said Puneet
Dewan. 
Innovations in care delivery
“Remote service provision has come to
stay due to Covid-19,” said Ifeanyi
Nsofor, CEO of EpiAFRIC and Director of
Policy and Advocacy at Nigeria Health
Watch. And everyone now sees the value
of care close to home (primary care). 
Indeed, because of lock-downs and
physical distancing requirements,
tremendous advances have been made
in the area of tele-health, online
consultations, house calls by doctors,
use of call centers, e-pharmacies, use of
digital adherence technologies (e.g.
smart pillboxes, video observed
therapy), and home delivery of
medicines using health workers, ride-
sharing services, etc. All of these can
and should be leveraged for TB, at a
larger scale than what is currently
happening. 
Coronavirus emergency (Covid 19). Volunteers of the
Italian Red Cross engaged in the delivery of ... [+]
MONDADORI PORTFOLIO VIA GETTY IMAGES
“Covid-19 is providing a huge boost to the at-home
delivery market for medicines,” said Prashant Yadav, a
supply chain expert and professor at INSEAD. “The
infrastructure that many privately funded startups &
social enterprises are creating could be extremely useful
for TB patients especially if sometime in the future we
transition to even shorter treatment regimens which can
be self-administered with a tele-consult follow-ups,” he
added.
Indeed, we now have hopes for a 1-month treatment for
latent TB infection, a 4-month treatment for active TB,
and a 6-month oral treatment for drug-resistant TB. If
these can be combined with tele-consults and at-home
delivery of medicines, it could revolutionize TB care.
According to Yadav, Covid-19 has created a sudden and
growing interest in improving healthcare supply chains.
“Many of the initiatives are focusing on resolving system
bottlenecks in procurement, distribution and supply
chain information systems. These will go a long way in
ensuring healthy supply chains for all medicines,” he said.
Better data, data visibility and usage
Most TB programs still rely on annual reports and paper-
based reporting systems that are no longer fit for
purpose. Covid-19 shows us the power of real-time data
aggregation, analysis and usage. 
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Infection control & behavior change 
Despite being an airborne respiratory
infection with high risk of occupational
transmission, TB infection control has
received little attention in high-burden
countries. Covid-19 shows that
healthcare systems can find ways to
protect healthcare workers and people
can change their behaviors to reduce
risk, for themselves and others. 
“The overlooked story is how human
behavior change can interrupt
transmission. A no holds barred attack on
how we change behavior should be
essential response to this pandemic and
TB,” said Peter Small. 
Routine use of personal protection
equipment by healthcare workers, large-
scale use of face masks by the public,
better triaging and cohorting within
health facilities, safer disposal of
respiratory secretions, and advances in
research into aerosols & airborne
transmission (and engineering controls)
can all help interrupt TB as well as Covid-
19 transmission. 
Because of Covid-19, the use of face
masks has become less stigmatized, and
there is wider acceptance that anyone
can get a respiratory infection. Hopefully,
this will make TB less stigmatized. 
Social safety
Covid-19 has taught the world about the
importance of social safety nets that
include paid sick leave, unemployment
benefits, direct cash transfers, food
supplements, and a heightened focus on
social determinants. Greater education of
the public and community engagement is
also evident in many settings. And public
health investment is now clearly
understood as a ‘social good.’ 
During this pandemic, an astounding number of
real-time Covid-19 trackers, vulnerability indices,
geospatial mapping tools and dashboards have
been launched, often by collaborative networks of
scientists and citizens. This has provided real-
time data for public health and personal use.
Rapid data sharing has also provided early
epidemiological and clinical insights. Most
countries are conducting rapid prevalence and
infection surveys, to enhance routine surveillance.
Covid-19 has also accelerated the use of
electronic medical records. 
TB has never seen this level of investment in data
systems. Lack of good data has always blunted
effective TB response and made it harder to
ensure accountability.
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“Investments on data systems and tools like
vulnerability indices are key to deploying a more
precise response (for Covid-19 or TB),” says Sema
Sgaier, Director of Surgo Foundation.
“Vulnerability indices can be powerful predictive
tools that enable policy makers to identify
geographies that will have the hardest time to
mitigate the health, social, and economic impacts
of a disease like TB, and guide policy makers to
the types of mitigation interventions they should
be betting on,” she added. Machine learning and
big data can also help precisely target those who
need extra support.
Since TB is primarily a disease of poverty and
is highly correlated with social determinants
such as malnutrition and poor housing, such
social security benefits must be more widely
available to all persons with TB, especially in
low- and middle-income countries. A purely
biomedical approach to TB is unlikely to
succeed. In the same vein, greater
engagement of communities most affected
by TB is critical for success.
Public-private partnerships for care
delivery 
During this crisis, governments across the
world have found a variety of mechanisms
(e.g. price caps, strategic purchasing of
services, better regulation) to tap into the
private health sector for Covid-19 testing and
treatment. As noted by WHO, many LMICs
have a large and growing contingent of
private sector health service delivery actors
that have historically been weakly governed
and poorly coordinated. “Now more than ever
LMICs need a whole-of-government and
whole-of-society approach as they immerse
in the battle against COVID-19.” 
A recent survey showed wide variations in
the cost of Covid-19 testing in the private
health sector across LMICs. However, some
countries have successfully made Covid-19
testing more affordable and accessible via
private laboratories. Similar private-provider
initiatives are also underway for TB, and
deserve to be taken to scale, since the
private health sector is a major source of TB
care in several high TB burden countries. 
Global partnerships & collaborative
research
The pandemic has transformed medical
research and publishing. We now have rapid
access to information via pre-prints and
open access publications. Most medical and
scientific conferences are now free and
easily accessible to people around the world. 
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There are many open data platforms to foster
research collaborations & R&D. “Despite TB
being the biggest infectious diseases burden,
and especially affecting LMICs, many
publications are still sitting behind a paywall,”
laments Muge Cevik, a clinical lecturer in
infectious diseases at the University of St
Andrews. 
The pandemic has also inspired several
multilateral global collaborations and
partnerships (e.g. ACT Accelerator, COVAX),
pooling of funding for new tool development &
delivery, patent pools to increase access, and
other approaches to increase access to new
tools. 
Such partnerships are urgently needed for TB,
where slow access to new tools is a long-
standing concern. ‘We have demonstrated that
with global solidarity, a lot can be achieved in a
short time. Open data, open access research and
(to some extent) pooling of technology have all
become the norm and should be continued for
global threats like TB,” said Soumya
Swaminathan, Chief Scientist at WHO. 
Rapid, multi-centric trials & evaluation studies
(e.g. Solidarity trial, Recovery trial), faster
regulatory approval processes, greater
cohesion among scientists for evidence-driven
interventions (e.g. John Snow Memorandum),
and multi-sectoral responses within and across
countries have all been noticeable during this
crisis. “Wouldn't it be great to see the same
concerted efforts to develop TB drugs and tests
as we've seen for Covid-19?” asked Antonio
Flores. 
Muge Cevik would like TB researchers to be
more open to adaptive clinical trial designs. “It
seems like we are constantly stuck in long
phase 3 studies of single drugs,” she lamented.
“Now more than ever LMICs need a whole-of-
government and whole-of-society approach as
they immerse in the battle against COVID-19.” 
Jennifer Furin, a TB physician and
advocate, laments that TB has received
almost no attention compared to Covid-
19, despite the fact that TB kills millions of
people each year. “Research predicts a
gloom-and-doom scenario for TB as a
result of Covid-19, but if we are smart,
persistent, and creative in adapting some
of Covid-19's successes, this could actually
become our finest hour,” she argued. Along
with her colleagues, she has listed
potential collateral benefits from the
Covid-19 pandemic to TB and HIV
services. 
Aakriti Pandita, an infectious diseases
physician at the University of Colorado
has survived both Covid-19 and TB.
“Covid-19 is unclogging many novel
pathways towards medical advancement
that otherwise would have taken a lifetime
to develop. In fact, in time, Covid-19 may
actually prove to be one giant leap in
medical science and global health if we use
it our advantage,” she said.
Beyond disease silos
While the Covid-19 crisis has brought a
great deal of attention to health, it is
unclear whether such interest will sustain
when the crisis dies out. Will Covid-19
create more disease silos, or will we finally
see stronger health systems that can offer
better primary healthcare? Will countries
continue to invest in public health? 
Daksha Shah, Deputy Executive Health
Officer for the Municipal Corporation of
Greater Mumbai in India has coordinated
services for both TB and Covid-19. “Right
now, the health system is most receptive
(she highlighted the “My Family, My
Responsibility” campaign in her state as an
example) and we should build on this for
improving care for TB, non-communicable
diseases, and other conditions,” she said. 
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Grania Brigden, Director of the TB Department at
The Union agrees. “I, personally, do not want to see
another vertical disease program established with
separate funding streams/ donors/ multinational
organizations,” she said. “I think there is a benefit to
thinking how/if TB integrates with the Covid-19
response and in high burden contexts becomes the
cornerstone of a comprehensive approach to lung
health,” she added. Since Covid-19 has put the
spotlight on the importance of comorbidities, she
hopes a similar attention will be paid to addressing
comorbidities that often accompany TB (e.g. HIV,
diabetes, malnutrition). 
Yogan Pillay, country director of CHAI in South
Africa, sees great potential for leveraging Covid-19
innovations for TB. The problem, he said, is “none of
these are new to the TB community. How to get
everyone to take TB seriously as they are with
Covid-19?”, he asked. 
Jennifer Furin has similar concerns. “The dazzling list
of innovations for Covid-19 only happened because
wealthy nations are just as at risk of Covid-19 as
poor nations,” she said. “So we need to be fierce
advocates to make sure these tools for Covid-19 are
applied to TB because rich countries have revealed
themselves for what they are: self-interested to the
core,” she added. 
Jennifer Furin is right - the billions of dollars
invested in Covid-19 vaccines is orders of magnitude
higher than the investments made in TB vaccine
development since the dawn of humankind. We
might have Covid-19 vaccines within a year, but will
still be using a 100-year old vaccine for TB next year. 
Saurabh Rane, a drug-resistant TB survivor and
advocate has a compelling message. "I don't want to
know why the world didn't respond this way for TB
when it kills over a million people every year. But
now that we are building tools to fight Covid-19, I
beg everyone to use them to fight TB as well," he
said. I agree wholeheartedly with him. There cannot
be a more opportune moment for the TB community
to leverage Covid-19 innovations to reimagine TB
care, and make universal health coverage a reality.
The need to find game-changing
yet feasible solutions to
overcome the TB problem has






Dr. Shingar Sharma, Formerly Grant
Advisor, WT-DBT India Alliance, New
Delhi & Dr. Pawan Sharma, Formerly
Senior Research Scientist, ICGEB, New
Delhi
A six-month-long duration of TB treatment
under the DOTS programme is fraught with
issues like non-compliance by patients, mix
up of drugs, etc., contributing to the
emergence of multi-drug-resistant TB.
Shortening the duration of treatment has
been a priority area in the TB drug discovery
research efforts. In a recent Phase 3 clinical
trial (Study 31/A5349), a 4-month regimen is
as efficacious as the 6-month regimen for
treatment of drug-susceptible tuberculosis
in patients. This landmark breakthrough is
expected to strengthen the global efforts
for the elimination of TB by 2030.
According to the WHO Global TB report, there
were an estimated 10 million new cases of TB
worldwide in 2019 and approximately 1.5
million people died due to the disease. India
accounted for 26% of the global TB burden, the
highest among all countries. Though the
numbers have been falling over the past years,
the progress is too slow. Disruptions in health
services and case reporting due to the COVID-
19 pandemic have caused a setback in the
efforts to achieve the Sustainable
Development Goals and can derail the
ambitious End TB Strategy which aims to
reduce TB deaths by 90% by the year 2030. The
ongoing Covid-19 pandemic has not only laid
bare the abject unpreparedness of countries
across the world to effectively deal with such a
massive health emergency but also poses a
grave threat to the gains made in combating
other major global diseases, such as
Tuberculosis (TB). TB continues to be a leading
cause of death worldwide and has not halted
its grim march even as Covid-19 is taking a toll
on health systems everywhere. 
The need to find game-changing yet feasible
solutions to overcome the TB problem has
taken on even greater importance in
unprecedented times like these. Drug-resistant
TB remains a formidable threat and radical
approaches are required to stem its onslaught.
India had the largest number of drug-resistant
cases in 2019, amounting to 27% of the global
burden (WHO report 2020)[1]. Although the
current new TB drug pipeline reflects
impressive international effort in developing
new anti-TB drugs {Table}, research on cutting
down the duration of a long treatment















































Current treatment regimens for TB are
prolonged, intensive and complex, and often
result in mismanagement by healthcare
providers (the wrong combination of drugs
prescribed or inappropriate length of
treatment) or non-compliance by patients.
In some regions, drugs may not be readily
available or may be of poor quality. These
issues of mismanagement and non-
compliance have given rise to several drug-
resistant strains of Mycobacterium
tuberculosis. Given this situation, there is a
great emphasis on developing shorter
regimens. Though research on this front has
been going on for several decades, it is only
this year that a major breakthrough has
been reported. An international,
randomized, Phase 3 clinical trial called
Study 31/A5349, has shown that a
shortened four-month daily treatment
regimen is as safe and effective as the
standard six-month daily drug therapy. The
trial, led by the U.S. Centers for Disease
Control and Prevention’s (CDC) Tuberculosis
Trials Consortium (TBTC) in collaboration
with the AIDS Clinical Trials Group (ACTG)
was conducted at 34 clinical sites in 13
countries with more than 2,500 participants,
including 214 people with HIV. The study
tested the safety and efficacy of two four-
month regimens containing high doses of
rifapentine to treat drug-susceptible TB. Out
of the two regimens, the one that included
moxifloxacin (2PHZM/2PHM) showed
promise. It included eight weeks of daily
treatment with high-dose rifapentine,
isoniazid, pyrazinamide, and moxifloxacin
and nine weeks of daily treatment with
rifapentine, isoniazid, and moxifloxacin. The
treatment was well-tolerated and found to
be non-inferior in efficacy to the standard
six-month regimen (2RHZE/4RH) which
includes eight weeks of daily treatment with
rifampin, isoniazid, pyrazinamide, and
ethambutol and 18 weeks of daily treatment
with rifampin and isoniazid. 
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These findings, presented at the 51st Union
World Conference on Lung Health[2], (held
virtually on Oct. 20-24, 2020), are nothing
short of ground-breaking. A shortened course
would be more convenient, economical and
most likely boost patient compliance. The
shorter duration would hopefully mitigate the
dire consequences of interruptions in the
longer standard regimen and thus prevent
emergence of drug-resistant cases. However,
it remains to be seen how well these findings
translate to actual clinical practice. It would
be important to examine the safety and
efficacy of the short-course treatment in
different ethnicities and more vulnerable
populations. TB disease is a wide spectrum
and manifests in highly varied forms in
individuals. Moreover, the current uncertainty
and socio-political instability in many parts of
the world can also have an enormous impact
on the ability of countries to implement new
treatment regimens for the masses.
Nevertheless, the success of this trial will
surely generate immense buzz in the TB
research community and also serve to
strengthen the hope that other advancements
in TB treatment are still very much possible
even if the journey is extremely arduous. The
TB drug clinical pipeline has many candidates,
existing and novel, as well as novel regimens
being tested in various trial phases. The
outcomes of these trials are eagerly
anticipated and further success could
tremendously bolster TB control programmes
around the world, especially in high burden
countries like India.
In some regions, drugs may not be readily
available or may be of poor quality. These
issues of mismanagement and non-
compliance have given rise to several
drug-resistant strains of Mycobacterium
tuberculosis. 
References:
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Vaccines have played a major role in our
efforts to control many bacterial and viral
infectious diseases. Smallpox is the classical
example of a viral disease that has been
eradicated primarily by using an effective
vaccine.
Dr. M.S. Jawahar, MD, MSc (CDE), DipLSHTM,
Former Scientist G, ICMR, National Institute
for Research in Tuberculosis, Chennai
India has a comprehensive immunization
programme for infants and children
under the National Health Mission (1).
The Expanded Programme on
Immunization launched in 1978 was
renamed as Universal Immunization
Programme (UIP) in 1985 and has been
an integral part of the National Rural
Health Mission from 2005. It is one of
India's largest public health programmes
targeting close to 2.67 crore newborns
and 2.9 crore pregnant women annually.
Under the UIP, immunization is providing
free of cost against 12 vaccine
preventable diseases: diphtheria,
pertussis, tetanus, polio, measles,
rubella, severe form of childhood
tuberculosis (TB), hepatitis B, meningitis
& pneumonia caused by Hemophilus
Influenza type B, rotavirus diarrhoea,
pneumococcal pneumonia and Japanese
Encephalitis. The two major milestones
of UIP have been the elimination of polio
in 2014 and maternal and neonatal
tetanus in 2015.
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Unfortunately, for TB, an ancient scourge
that has afflicted mankind since antiquity
and that still affects more than 10 million
persons annually with 1.4 million deaths
(2). We do not have an effective vaccine.
BCG (Bacillus Calmette Guerin), the only
licensed vaccine for TB currently, was
developed by Frenchmen Albert Calmette,
a physician and microbiologist and Camille
Guerin, a veterinarian, by attenuating
Mycobacterium bovis over 230 cycles
between 1908-1919 (3). BCG was first used
for human immunizations as early as a
century ago in 1921 by the oral route. The
League of Nations, the precursor of the
World Health Organisation (WHO) adopted
BCG as a standard vaccine for human TB in
1928. However, the use of BCG suffered a
setback in 1930 when 207 of 252 children
who received the vaccine in Lubeck,
Germany, developed active TB and 72 of
them died. The vaccine came from Pasteur
Institute in Paris but was contaminated
with Mycobacterium tuberculosis in the TB
laboratory in Lubeck. Although BCG
vaccine itself was eventually exonerated,
its use declined for several years
thereafter.
In India, BCG vaccination was first
introduced on a limited scale in May 1948.
The BCG Vaccine Laboratory was set up in
Chennai (then called Madras) in the same
year and in 1949 BCG vaccination was
extended to schools in almost all the
States of India. The International TB
Campaign helped to scale up by
conducting BCG vaccination
demonstrations in five centres starting
with Madanapalle in Andhra Pradesh. The
Programme was expanded through mass
campaigns in 1951 supported by the United
Nations International Children's
Emergency Fund (UNICEF) and WHO. By
1956 the campaign covered all the States
of India. BCG became part of the National
TB Control Programme in 1962.
Even though BCG is the most widely used
vaccine (120 million/year) in the world, its
efficacy against TB is one of the most debated
issues. To test its efficacy in the Indian
population a randomized clinical trial (RCT) was
started in Chengleput in South India by the
Tuberculosis Chemotherapy Centre (TCC), later
renamed the Tuberculosis Research Centre
(TRC) and subsequently as the National
Institute for Research in Tuberculosis (NIRT) of
the ICMR, in 1968. The Chengleput trial was the
world’s largest BCG vaccine study. It was a
double blind, parallel-arm, placebo controlled
RCT covering a population of 3,66,000
individuals in Chengleput district of South India
close to Madras. Two strains of BCG (French
and Danish) and 2 doses (0.1 mg; 0.01 mg) of
each were used and compared to a placebo. The
study population was followed up for 15 years
by resurveys every 30 months. Two reports (7.5
years and 15 years) were published (4,5).
The results of the study came as a surprise to
the Indian and international community. It
showed overall, that neither of the two strains
of BCG in either dose offered protection against
adult forms of pulmonary TB. However, a
modest protection of 21-32% was seen in
children 1-9 years of age. These results were
hugely disappointing and prompted further
research to identify the causes of the failure of
the vaccine. A rigorous evaluation by Indian and
International experts of the methodology of the
trial did not reveal any methodological flaws.
The efficacy of BCG vaccination has varied in
different populations ranging from 0-80%
(Figure 1). In RCTs in British school students,
infants in Chicago and in North American
Indians the efficacy has been as high as up to
80% whereas in other states in the USA
(Georgia, Alabama) and in South India the
vaccine has offered no or little protection.
However, case control studies over different
geographic locations have shown modest to
significant protection, especially against
military and disseminated TB.
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c) Prior exposure to non-
tuberculous mycobacteria could
result in a nonspecific immune
response against mycobacteria
that could interfere with efficacy
of BCG by a process of either
‘Masking’, as already there is a
level of immunity and BCG is not
adding to this, or by ‘Blocking’
that prevents BCG from
replicating and stops it from
producing an immune response. 
d) Interference by concurrent
parasitic infection. Th1 response
is required for an effective
immune response to TB infection.
Concurrent infection with
parasites can produce a
simultaneous Th2 response that
could blunt the effect of BCG.
In view of these varied responses
the WHO has made the following
recommendations (7): 
a) In high TB burden countries, a
single dose of BCG vaccine should
be given to all infants soon after
birth. Revaccination is not
recommended. 
b) BCG vaccine should not be
used in HIV infected children,
even if they are asymptomatic. 
c) Low TB burden countries may
choose to limit BCG vaccination
to neonates and infants of high-
risk groups for the disease or to
skin-test negative older children. 
d) BCG vaccination of adults is
not recommended.
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A systematic review and meta analysis of RCTs in
pulmonary and meningeal and miliary TB showed
higher protection with increasing latitude. Protection
was greater when BCG was given in infancy or at
school age, when prior sensitization was excluded.
Protection against meningeal and miliary TB was
greater than for pulmonary TB. Protection was also
higher with a lower likelihood of diagnostic detection
bias. There was little evidence that other study
characteristics or vaccine strain was associated with
protection (6).
It was assumed that the possible reasons for the
variable efficacy of BCG could be: 
a) Genetic variability among the strains of BCG. Six BCG
strains are in use in international immunization
programs (BCG Pasteur 1173 P2, BCG Danish1331, BCG
Glaxo 107, BCG Tokyo 172-1, BCG Russia-I and BCG
Brazil). These six BCG strains exhibit different
characteristics of attenuation and protection in animal
models. 
b) Genetic variation in populations. 
Figure 1: Efficacy of BCG vaccine in randomized clinical
trials and case-control studies in different populations
Figure 2
The End TB Strategy of the WHO based on
the United Nation’s Sustainable
Development Goals (SDGs) envisages a
Vision of a world of ‘zero’ deaths, disease
and suffering due to TB’, and aims at a
95% reduction in deaths, 90% reduction
in the incidence of the disease by 2035
compared to 2015 (8). The National
Strategic Plan of the Government of India
to eliminate TB (9) is even a more
ambitious, planning to reach these goals
set by WHO by the year 2025. The current
rate of decline of TB incidence globally is
a mere 2% per year (Figure 2). To reach
these goals set by the WHO this rate of
decline has to be steeply increased and
for this to happen new vaccine(s) against
the disease are desperately and urgently
needed. However this is easier said than
done as there are many challenges to be
faced for the development of a new TB
vaccine. Our knowledge and
understanding of the immune system in
TB is still inadequate. As yet there is no
good correlate for protection and there is
no suitable animal model. Funding is
available primarily from governments
and charitable organizations as TB is not
high priority for pharmaceutical
companies that are profit oriented. And
many TB endemic countries lack the
infrastructure for large-scale clinical
trials that will be required to evaluate
vaccine candidates.
New TB vaccines
However, driven by the compulsions and urgency
of the global need to rein in and reverse the TB
epidemic there has been a welcome and concerted
effort in the research and development of new
vaccines against TB in the last two decades (10).
Under the aegis of aeras and later the
International AIDS Vaccine Initiative (IAVI), funded
in main by the Bill and Melinda Gates Foundation,
many thousands of potential TB vaccine
candidates were identified and have gone through
the stages of preclinical evaluation in animal
models and a handful have qualified for clinical
studies in humans to date. Similarly in Europe, the
research promoted by the different European
Commission Framework Programs has resulted in
several potential TB vaccine candidates. The
European TB Vaccine Initiative (TBVI) is a non-
profit organization that facilitates the discovery
and development of new, safe and effective TB
vaccines and biomarkers that are accessible and
affordable for global use. 
Efficacy trials of new prophylactic TB vaccines
could target either the prevention of infection
against Mycobacterium tuberculosis (POI), or the
prevention of acquiring TB disease (POD) and the
prevention of recurrent TB disease (POR). POR
trials evaluate therapeutic vaccines administered
as an adjunct to drug treatment to increase the
effectiveness and shorten the duration of TB
treatment in patients undergoing TB treatment for
active disease.
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New TB vaccine candidates in
clinical trials can be either whole
cell vaccines, consisting of a) live
or attenuated Mycobacterium
tuberculosis strains, b)
Mycobacterium bovis BCG, c)





subunit vaccines that contain
Mycobacterium tuberculosis
antigens expressed as a)
recombinant proteins formulated
with different adjuvants or b)
expressed by recombinant viral
vectors used as vehicles for the
administration of antigens. 
Currently, 14 TB vaccine candidates
are being studied in Phase 1 to
Phase 3 RCTs in children and adults
(11). Of these, eight are based on
whole-cell mycobacteria and six on
subunit candidates (Table). Of the
whole-cell mycobacterial





(MTBVAC and GamTBVac), and four
are based on inactivated/ extracts
of mycobacteria (MIP, DAR-901,
RUTI, AEC/BC02). Of the subunit
candidates, three are
mycobacterial fusion protein(s) in
new adjuvant formulations
(ID93:GLA-SE, H56:IC31 and
M72:ASO1E) and three are based on
recombinant live-attenuated or
replication-deficient virus-
vectored entities expressing one or
more Mycobacterium tuberculosis
proteins (Ad5Ag85, ChadOx1.85/
MVA85A and TB/FLU-04L). 
Recently there has been encouraging news that in
infected adults, the adjuvant vaccine M72/AS01E has
shown 54% protection against active pulmonary
tuberculosis disease, without evident safety concerns
(12). Of particular interest to us in India is a Phase 3
multicentre double blind, placebo controlled RCT that
is studying the safety and efficacy VPM1002 and
Mycobacterium indicus pranii (MIP) in preventing TB in
household contacts of TB patients on treatment.
VPM1002 is a live-attenuated, recombinant BCG and
results from phase 1 and 2 clinical trials have
confirmed the pre-clinical data and have shown that
VPM1002 is at least as safe and immunogenic as BCG.
MIP, earlier known as Mycobacterium w, is a non
pathogenic mycobacterial species known to be
protective against leprosy. The origin of the proposed
name is a combination of the site of isolation of the
bacterial species from India (indicus), discovery by
Pran Talwar (pranii) and characterization at the
National Institute of Immunology, India (pranii). The
trial has completed recruitment of 12000 participants
(13). Results are eagerly awaited.
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M. Tuberculosis and HIV-Prolific
Killers in Developing Countries are
Syndemic Pathogens
Mycobacterium tuberculosis (Mtb) infection
accounts for the highest number of human deaths in
low- and middle-income countries of the world. Mtb
is also the most common opportunistic infection
accompanying HIV infection. The death rate for
combined Mtb/HIV infection is almost three-fold
higher when compared to Mtb infection of HIV-
seronegative patients, and the increase is not due
simply to depletion of CD4 T cells due to HIV. The
increased risk of mortality is due to a syndemic
interaction between the two pathogens that leads to
advanced immunodeficiency, chronic immune
activation, and increased disease dissemination.
Because of the synergy, eradication of MTB is
dependent on the eradication of HIV. Though
HIV/AIDS is often described as incurable, the recent
“shock-and-kill” strategy to eradicate HIV holds
promise for the eradication of MTB. Co-infection also
amplifies transmission of multidrug-resistant
tuberculosis (MDRTB), which besides requiring
longer treatment has a very low success rate.
Pending effective vaccine development, there is a
need to identify newer targets for the development
of drugs to treat MDRTB & XDR-TB.
Dr. M.V. Hosur, National Institute of
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According to a World Health Organization
(WHO) report, non-communicable diseases
accounted for 74% of deaths globally in 2019 [1].
Major contributors to this class are neurological
disorders, cancer and ischemic heart diseases.
However, when only low- and middle-income
countries (LMICs) are considered, communicable
diseases which include tuberculosis, HIV/AIDS
and malaria, are the highest killers. Though
tuberculosis (TB) is one of the oldest (>4000
years?) known human diseases, it is not yet
eradicated, and still is one of the major causes of
mortality. This is essentially because of the
lifestyle of Mtb inside the infected host cell. We
still do not completely understand how Mtb
manages to evade the human immune system to
survive and spread within eukaryotic cells. We
also do not understand how the bacterium
develops resistance against drugs. The problem
is further compounded by the fact that Mtb
infection is facilitated in HIV-positive individuals
with a 20-fold increase in the risk of infection
compared with HIV-seronegative individuals.
Analysis of samples from co-infected patients
was found to contain more drug-resistant Mtb.
Besides, millions of people are developing
cancers as a direct result of preventable
infections by bacteria and viruses. Hence,
infectious diseases will remain a major threat to
humankind, especially in LMICs. The United
Nations’ (UN) Sustainable Development Goal
(SDG) 3 seeks to end the TB epidemic altogether
by 2030. Although there is a decline in the
incidence of TB, the decline has been slow,
because gaps in preventing, diagnosing and
treating TB remain. Without new tools and
strategies, the UN targets are unlikely to be met
even by 2050. We, therefore, need to completely
understand at the molecular level the infection
and co-infection processes to form effective
strategies of treatment, and also to identify
newer targets for drug development [2].
Mtb infection
Mtb is a rod-shaped bacillus with a
diameter of about 300 nm (Figure 1,
page 22). It is an extremely slowly
growing bacterium (doubling time 18 –
24 hours compared to 20 minutes for
E.coli), requires oxygen, and contains an
unusual cell wall rich in mycolic acid.
This special cell wall is less permeable
to drug molecules, and it also makes
detection of the bacterium more
difficult.The DNA genome of Mtb
(H37Rv) consists of 4.4 × 106 base pairs
with approximately 4,000 genes, and
the gene make-up equips the bacterium
for survival in glucose-deficient and
fatty-acid rich environment. The
genome has evolved to encode proteins
that help the bacterium evade the
human immune response. The tubercle
bacillus spreads from person-to-person
almost exclusively by aerosolized
particles contained in aerosol droplets,
and one to five bacilli may suffice to
transmit the infection by air.
Macrophages, dendritic cells, and
neutrophils are the predominant
phagocytic cells that Mtb can infect
using a variety of receptors including
ten different Toll-Like-Receptors (TLRs).
Each of these receptors activates
different signaling pathways in the
bound cell. Bacterial activation of
surface toll-like receptors on
phagocytes induces TNF, IFN-γ, IL-1β, IL-
6, IL-12, IL-10 and TGF-β, activating
phagocyte and recruited T-cell
functions. Though TB is primarily a
pulmonary disease, it has other variants
where the bone, the central nervous
system, and other organ systems are
affected, especially when co-infected
with HIV.
Once the presence of MTB in the alveolar
space is detected by the patrolling
dendritic cells, the innate immunity
comprising of phagocytic immune cells tries
to clear the infecting pathogen.The efficacy
of the immune response, however, depends
on the genetic make-up of both the host
and the pathogen. For example, Mtb
utilizes several tricks to derail pathogen
destruction through the fusion of
phagosome with the lysosome. When all
infecting Mtbs are not cleared, Mtb is said
to have infected the host (Figure 2). TB
disease is of two different types – latent TB
and active TB. In the latent TB, the bug is
dormant, and there are no symptoms of
infection. In the active TB, on the other
hand, the bug can spread within the host,
and there are symptoms like cough with
sputum and blood, chest pains, weakness,
weight loss, fever and night sweats.It is
observed that only 5 - 10% of total Mtb
infections are in the active TB category.
The adaptive or acquired immunity tries to
prevent dissemination of infection within
the body.
The outcome of a successful adaptive immune
response from the host is the formation of what
are called granulomas, which are organized
immunological structures composed of T cells
macrophages, B cells, NK cells, dendritic cells
and other immune cells that surround Mtb to
prevent Mtb dissemination.Formation of the
Mtb granuloma during latent infection is
associated with a strong localized and systemic
proinflammatory response. The pathogen can
stay in a latent state for many years but can be
reactivated over a lifetime to cause disease and
become transmissible. Disrupting the integrity
of the granuloma is one way of shifting the
infection from a latent state to an active disease
state. Results of recent positron emission
tomography and computer tomography
experiments on HIV/Mtb co-infection reveal a
correlation between alterations in the number
and nature of granulomas and reactivation of
the disease, leading to the model shown in
Figure 3 [3]. Similar synergy likely prevails
during Mtb/HIV co-infection.
Figure 1. Electron micrograph showing
the rod-shaped mycobacterium
tuberculosis.
Figure 2. Mtb life cycle[13]
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The extent of infection and the intra-species
transmission from one individual to another
depend on the population dynamics, as well as,
on several geographical and climatological
factors.
Human Immunodeficiency Virus (HIV)
HIV is an enveloped retrovirus that causes
infectious disease HIV/AIDS. This virus was
discovered in 1981, and therefore is
relatively new compared to MTB
bacterium. A most disturbing feature of
this virus is that it attacks the human
immune cells that help the body to fight
infection. These cells include T-
lymphocytes (also known as T cells),
monocytes, macrophages and dendritic
cells that express CD4 protein on their
surface. The CD4 count (CD4 cells per
millilitre of blood) is used to describe the
severity of the disease. A count below
200is associated with full-fledged AIDS
when the body immune system is badly
damaged.
The glycoprotein, gp120, in the viral
envelope binds to CD4 and CD8 proteins on
the cell surface. Besides, a co-receptor
protein is also required on the cell surface
for the virus to gain entry into the cell.
There are two known co-receptors, CCR5
and CXCR4, and different strains of HIV use
different co-receptors. The virulence of
the virus using either co-receptor appears
to be different. The life cycle of HIV, shown
in Figure 4, comprises of seven stages: 1)
receptor-binding, 2) membrane fusion, 3)
reverse transcription of the viral RNA
genome, 4) integration of viral cDNA into
the host chromosome, 5) production of
viral RNA and proteins, 6) virus particle









Any molecule that can effectively interfere with
these steps in the viral life cycle would be a
potential anti-HIV drug [4]. The viral genome
encodes for six proteins Tat, Rev, Nef, Vif, Vpr
and Vpu, which play a regulatory role and
control the ability of HIV to infect a cell, evade
the immune response, multiply and exit to
infect other cells. The viral genome also
encodes for three enzymes to help in its
replication: 1) reverse transcriptase –
conversion of the viral RNA genome into cDNA,
2) integrase – incorporation of viral cDNA into
the host chromosome, and 3) protease –
cleavage of newly translated viral polyproteins
into different functional proteins through
cleavage of specific peptide bonds in the
polyprotein.
Inhibition of these enzymes would be a
scientific method of treating HIV/AIDS
infection. Indeed, many of the anti-AIDS drugs
developed using structural information
obtained through crystallography, and used in
anti-retroviral-therapy (ART), are members of
these three classes of inhibitors [5 -7]. The
situation, however, is not so simple. The virus
can stay undetected inside the human body in
the integrated state (pro-virus) for long
periods. These latent-cells, which can
potentially be activated to produce active virus,
therefore are considered as reservoirs of the
virus. These latent-cells can’t be killed by the
immune surveillance system, and therefore,
HIV/AIDS is often described as an incurable
disease. The second complication is that of
drug-resistance through mutations in viral
proteins [8,9].
The synergy between HIV-Mtb coinfection
There are several bacteria and viruses that
successfully establish infections in humans
when the human immune system is weakened.
Such infections are described as opportunistic
infections. HIV infection weakens the immune
system by reducing the CD4 T-cell count to
values below the normal value of about 500–
1,200 cells/mm3. While many different types of
bacteria can infect when CD4 count is below
200, Mtb is the only bacterium that can
successfully infect an HIV-positive person even
when the CD4 count is in the range 200 -500.
This makes Mtb the most efficient opportunistic
pathogen, and also suggests synergy between
HIV and Mtb infections. The synergy is also
indicated by the observation that HIV-infected
patients have a 5–10% annual risk of developing
TB, compared with a risk of 5–15% over the
whole life-time for HIV-1-uninfected persons.
The central players in this synergy are the
functionally impaired T-cells and the cytokines
they secrete. TB remains the leading cause of
death among people living with HIV. As already
pointed out, loss of protective CD4 T cells is not
the sole reason for the increased susceptibility
of HIV positive people for Mtb infection. The
increase can be attributed to at least two
mechanisms: the increased reactivation of
latent TB or increased susceptibility to   
 exogenous Mtb infection. Different
experimental
Figure 4. Effect of Mtb infection on the life
cycle of HIV in co-infection [10].
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studies indicate the following factors as
responsible for the synergistic relationship
between Mtb and HIV, as shown in Figure 4
[10,11]:
1. Innate and adaptive Immune response to
latent Mtb infection creates an expanded
cellular niche (e.g activated CD4+ and CD8+
T-cells) susceptible to HIV-1 infection.
Increased CCR5 and CXCR4 surface
presentation on Mtb-antigen-specific CD4+
T-cells and increased CD38+/HLA-DR+ T-
cells.
2. MTb infection Increases secretion of
chemokines and proinflammatory cytokines
(e.g., TNF, IL-1, IL-6) and transcription
factors such as (NF-κB, AP-1, SP1, C/EBP
and NFAT5) causing increases in HIV-1
replication by about 30%, even in
bystander Mtb-uninfected cells.Increased
secretion of CCL5 enhances replication of
X4-tropic HIV-1 which causes much faster
progress toward AIDS.
3. Latent TB disorients the host immune
system making it easier for HIV-1 to evade
the human immune system and spread
quickly.
4. Mtb infection reactivates dormant HIV-1
(pro-virus) to multiply and spread in the
body and enhances viral reservoir cells.
Increased CXCL10 recruitment of HIV-1-
infected T-cells to Mtb microenvironment.
Enhanced recruitment of Mtb-specific T-
cells to the bone marrow would create
another niche for viral expansion and
replication,
5) HIV-1 infects activated Mtb-specific T-
cells, leading to their preferential
depletion. HIV infection also causes a
progressive loss of Mtb-specific T-cell
functions, including T-cell proliferation,
cytokine production, and cytotoxic
capacity. HIV infects and destroys
preferentially those T-cells (polyfunctional
T-cells) which protect against Mtb
infection.
6) This early CD4+ T-cell depletion and
increase in virus-containing CD8+ T-cells
on HIV infection alters the cellular
composition of the granulomas
surrounding the Mtb-infected
macrophage (Figure 3). As a result, the
granuloma becomes structurally porous
and Mtb bacilli escape and spread the
infection to other parts of the body.
7) HIV infection renders T-cells
dysfunctional by chronic activation, and it
also disturbs the desired balance
between distinct T-cell populations, such
as the proportion between
naïve/effector/activated,
Th17/regulatory T-cells (Treg).
8) HIV-infection promotes Mtb infection
and active TB through up-regulation of
Mtb entry receptors on macrophages. De
novo Mtb reinfection in
immunosuppressed HIV-infected
individuals causes rapid progression to
symptomatic disease with survival times
as short as 14 days and fatality
percentages over 85%.
9) HIV infection delays the establishment
of Mtb antigen-specific immune
responses by impairing TNF-mediated
macrophage apoptosis.
Treatment of HIV-Mtb coinfection
There is clear evidence that providing
antiretroviral therapy to HIV-infected
adults during tuberculosis treatment
reduces mortality. Treatment should be
initiated without any delay as the
probability of emergence of drug-
resistant Mtb is significantly enhanced by
co-infection with human
immunodeficiency virus (HIV) [12].
However, the detection of Mtb infection is
made more difficult by the co-infection.
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Drug resistance
Several drugs, to be taken for 6 – 12 months,
have been in use to treat tuberculosis, and the
most popular first-line drugs are rifampicin
and isoniazid. Rifampicin inhibits elongation
of mRNA by binding to the β subunit of the
RNA polymerase enzyme. Isoniazid is a
prodrug, which once activated by the
catalase/peroxidase enzyme of the host,
inhibits the production of mycolic acid
required for bacterial cell wall synthesis.
Mycobacteria develop drug-resistance and
cause MDRTB, XDR-TB and totally resistant
tuberculosis. Treatment of MDRTB and XDR-
TB takes longer, success rates are lower (55%
and 30%) and also costs prohibitively more (5
to 6 times more). Duration of survival to death
can be as short as two weeks.
Some of the mechanisms of resistance
development are: 1) Target alteration – reduce
drug binding through mutation of the target,
2) mimicking the target to sequester drugs
e.g. MfpA mimics DNA double helix thereby
sequestering DNA binding drugs, 3) inactivate
drugs through chemical modification, e.g. an
acetyltransferase, Eis (enhanced intracellular
survival) acetylates multiple amine groups of
aminoglycosidic drugs, 4) drug degradation by
Mtb enzymes and 5) drug efflux – at least 18
transporters in mycobacteria have been
found.
Drug-drug interactions
Treatment of co-infections is also beset with
the complexity of drug-drug interactions.
Drug interactions between antiretroviral and
anti-TB agents are common in the
management of patients with HIV and TB.
Drugs for HIV and TB don't always work well
together. For example, Protease Inhibitor
(PI)/ritonavir + rifabutin- the combination is a
prescribed treatment for HIV/TB. This
treatment regimen has the following problem: 
ritonavir-boosted PIs markedly increase rifabutin
concentrations and reduce its clearance
necessitating a reduction in the dose of rifabutin
by 50% to 75%. Toxicity (neutropenia, uveitis,
hepatoxicity, rash, gastrointestinal symptoms)
and suboptimal rifamycin exposures with reduced
dose may lead to drug-resistant bacteria. On the
other hand rifampicin-induced, cytochrome P450
activity may cause sub-therapeutic levels of PIs. It
is in-fact observed that co-treatment for TB and
HIV significantly increased the risk for major
mutations conferring resistance against PI.
Conclusions
TB remains a prime killer in the world of
infectious disease. While it does enter latency in
90% of cases, reactivation is possible, and co-
infection with HIV is found to be especially
effective in this. HIV has a profound effect on TB,
including faster rates of disease progression,
higher rates of drug resistance, and increased
mortality among patients with MDRTB. The co-
infection disturbs the nature and structure of
granulomas that isolate Mtb thereby facilitating
the dissemination of Mtb. In the co-infection, the
immune system is rendered dysfunctional thereby
promoting propagation of each pathogen.
Therefore, eradication of TB, a stated goal of the
UN, becomes dependent on the eradication of HIV.
Though the mechanism of HIV replication makes
HIV incurable, recent research on latency-
reversing agents (LRAs) is an effort to eradicate
HIV by the “shock and kill” strategy [2]. If
successful, this would help eradicate Mtb as well.
Co-infection is also observed to lead to the
emergence of MDRTB and XDR-TB, effective
treatment of which requires identification of
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Tuberculosis (TB) caused by
Mycobacterium tuberculosis,
and similar organisms (e.g., M.
bovis, M. pinnipedii etc.) has
been observed in a wide range
of species encompassing non-
human primates, elephants,
several wild ungulates (e.g.,
wild boar, red deer etc.),
carnivores, marine mammals
(e.g., the sea-lions and the
seals) and psittacine birds
(especially, the parrot family)
[1-5]. The extent of infection
and the intra-species
transmission from one
individual to another depend on
the population dynamics, as
well as, on several
geographical and climatological
factors [2]. The infection can
even get transmitted from one
species to another (especially,
in case of the wild ungulates)
based on the foraging patterns.
Experts and practitioners
associated with the TB have
mentioned that principally
‘Animal TB’ is caused by the
archetypical zoonotic pathogen
named M. bovis, which can be
transmitted from animals to the
human bodies and vice versa [6,
7].
From a conceptual perspective,
mere discovery of TB in wild
animals in any particular
environment is not sufficient to
conclude whether the affected
group (or species) is a self-
sustaining maintenance host or
a dead-end spill-over host.
Moreover, based on the basic
findings it  is  often  difficult  to 
TB in Zoo Elephants and the
Transmission of Infection into
Zookeepers due to Extended Proximity
during COVID-19 Pandemic
Tuberculosis in captive Asian elephants has been a
subject of interest among the experts and practitioners
for the past few decades. During COVID -19 pandemic, the
zoos remained closed and the caregivers had to spend
extended hours in the enclosures to help the elephants
get rid of boredom and depression. Such proximity
enhanced the chance of TB transmission from elephants
to human bodies. Hence, effective measures are needed
for early detection of TB infection in captive elephants to
curb further transmission.
Dr. Rudrodip Majumdar, Energy and Environment
Programme, School of Natural Sciences and
Engineering, National Institute of Advanced
Studies, IISc Campus, Bengaluru
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The tuberculosis in the captive
elephants (Elephant TB) has emerged as
a serious infectious zoonotic disease in
the past few decades [9, 10]. Three
elephants succumbed to the pulmonary
complications caused by M. tuberculosis
in an exotic animal farm located in
Illinois (USA) between 1994 and 1996. In
October 1996, a fourth living elephant
tested culture-positive for M.
tuberculosis [11]. A Swedish zoo
witnessed an outbreak of TB during
2001-2003, that involved five elephants
and several other species viz. giraffes,
rhinoceroses, and buffaloes. Four
different strains of M. tuberculosis
could be separated from those infected
animals [9]. Studies indicate that about
3% of captive elephants in the United
States were infected with M.
tuberculosis in 2000 [12, 13]. More
recent estimates by Mikota indicate that
the infected elephants may account for
~ 6% of the total captive elephant
population housed in various US zoos
[14]. It is also noteworthy that amongst
the captive elephants in the zoos and
the circuses, the Asian elephants
(Elephas maximus) are more frequently
detected to be infected with TB, as
compared to the African elephants
(Loxodonta africana) [14]. 
label those groups of wild individuals as
significant source of TB infection for livestock,
companion animals or humans. Such distinction
is critical for the development of strategies to
curb the large-scale spreading of the
dangerous zoonotic infection [6].
Inclusion of wildlife disease management as an
integrated part of the TB eradication
programme is a complicated process, as ethical
perspectives of the stakeholders and the level
of engagement are directly linked with the
identification of beneficiaries of the
programme. These aspects lead to a certain
level of difficulty in continued surveillance and
systematic study of the wild species (or
populations) for possible tuberculosis
infection. However, representative studies
conducted on the livestock, as well as the
specimens living in the menageries can unearth
important information about the transmission
of tuberculosis infection from the captive
animals to the human bodies and vice versa.
TB in Captive Animals and the Need for
Adaptive Diagnostic Tools 
It is important to mention that the
pathogenesis of tuberculosis bacteria, the
receptivity and immune responses to the
infection are found to vary widely in the
captive wild species living in the zoos. The
variation is even more prominent when the
comparisons are made between the zoo species
and the domestic animals. The diagnostic tools
usually used for the domestic animals tend to
show limited performance for the zoo species.
This necessitates the development of
customized, adaptive diagnostic tools for
detection of tuberculosis infection in different
species [8]. Recently, diagnostic tools based on
the investigation of humoral immunity have
paved a promising way towards detecting
antibodies directed against certain
immunogenic mycobacterial antigens in various
zoo species [8]. 
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The extent of infection and the
intra-species transmission
from one individual to another
depend on the population
dynamics, as well as, on
several geographical and
climatological factors.
Elephant TB: Diagnosis, Monitoring of
Treatment and Limitations
Following the untimely deaths of
several high-profile captive elephants
in the United States in the mid-1990s,
veterinarians discovered that those
animals were infected with the human
strain of tuberculosis (TB) [15].
Although awareness about the TB
infection in captive elephants has been
gradually increasing over the past few
decades, unfortunately anti-
tuberculosis therapy for these animals
has not been standardized yet.
Currently, the most reliable diagnostic
method for TB in captive elephants in
the USA is based on the culture of
respiratory secretions obtained by
washing trunks [12]. However, the trunk
wash culture method has serious
limitations, as it does not facilitate
rapid identification of infected
individuals. Therefore, innovative and
more efficient diagnostic methods are
needed for early diagnosis. Early
diagnosis results in timely initiation of
chemotherapy leading to more
effective control of TB. Although the
key mycobacterial antigens responsible
for elephant TB are yet to be
understood completely and the optimal
immunoassay formats are still not
established, serological methodology
has shown ample promise as a
diagnostic tool towards characterizing
the humoral responses associated with
elephant TB [14]. In quite a few cases,
anti-tubercular therapeutic doses
based on the humoral responses have
resulted in gradual decrease in the
antibody levels to certain antigens,
which hint at the possibility that the
serological methodology can be
effectively used for monitoring the
treatment.
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Usually, treatment of active TB in captive
elephants involves administering combinations
of Isoniazid (INH), Rifampin (RIF), and/or
Pyrazinamide (PZA) orally or rectally, daily or
every 48 hours for 6 months. Reported
indicative daily drug dose limits are 2.5 -7.5
mg/kg for INH, 8 -10 mg/kg for RIF, and 25- 35
mg/kg for PZA. Moreover, for treating
multidrug-resistant (MDR) TB, a combination of
PZA, ethambutol (EMB), enrofloxacin (ENRO),
and amikacin (AMK) is also used. The dosage
and the duration of treatment vary from one
elephant to another [14]. The preventive
therapy usually continues for 6 months.
Transmission of Elephant TB infection into
the Zookeepers
Following the deaths of the captive elephants
in the US-based exotic farm in Illinois in the
mid-1990s, twenty-two elephant handlers at
the farm were screened for tuberculosis (TB)
[11]. Eleven of the tested handlers showed
positive reactions to purified protein derivative
that was introduced through intradermal
injection. One handler exhibited smear-
negative, culture-positive active TB.
Comparison of DNA fingerprint using IS6110 and
TBN12 typing further unearthed the fact that
the isolates from the four elephants and the
handler with active TB belonged to the same
strain. 
This investigation formally brought forth the
evidence of transmission of M. tuberculosis
between humans and the elephants [11]. In July
2009, the routine screening conducted among
the elephant handlers and caregivers at a non-
profit elephant refuge in south central
Tennessee, USA exhibited conversion of
tuberculin skin test (TST) results from negative
to positive. Further, from the records of the
facility it was revealed that the trunk wash
collected in December 2008 from a quarantined
elephant contained M. tuberculosis [16].
Results also showed that the 
susceptibility of the employees to the
latent M. tuberculosis increased by more
than 20 times upon working for more than
4 hours in the quarantine facility during
2009. A study conducted in 2012 on 600
captive Asian elephants in Kerala, Tamil
Nadu and Karnataka exhibited high
prevalence of asymptomatic TB infection
of elephants in the captive Indian settings
[17]. In 2019, eight caregivers dedicated to
the pachyderms of Point Defiance Zoo in
Tacoma, Washington tested positive for
latent TB infection [18]. These
observations further stresses on the need
for early diagnosis in order to reduce the
risk of exposure and subsequent TB
transmission to the elephant handlers,
other zoo inmates, as well as the visitors.
Impact of COVID-19 on TB Transmission
between Captive Elephants and
Caregivers
According to Adam Langer, branch chief of
surveillance, epidemiology, and outbreak
investigations for the CDC, depending on
the environmental conditions TB bacteria
can remain suspended in the air for several
hours. The key deciding factors behind the
exposure risk include the concentration of
pathogenic load in the air, the duration of
exposure, the size, and the ventilation
system of the room [15]. Owing to the large
lung size of the elephants, a relatively
large number of bacteria are released into
the surrounding air from the infected
individuals during the breathing process.
Therefore, sharing air space with a TB-
infected elephant poses a higher risk of
transmission than the same exposure to an
infected person. Therefore, the handlers
and caregivers, who spend substantial
amount of time with the captive elephants
in the indoor environment of the zoo
enclosures, are highly susceptible to the
TB infections. During the ongoing COVID-19
pandemic, all the zoos and the menageries
with exotic collection of wild species  have
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remained closed in order to protect the zoo
inmates from the novel coronavirus SARS-
COV-2. However, during this period, many
captive animals have exhibited symptoms of
depression that are owed to the sudden
change in their respective lifestyles. Although
lesser crowd during the extended lockdown
period has helped some species to behave in a
more stress-free manner (e.g., the deer,
giraffes, kangaroos, lesser carnivores)
leading to better health and reproductive
behaviours; the species like the elephants
that are more attached to the human beings,
intelligent and responsive to the visitors,
have suffered heavily in terms of the
emotional health due to the extended
loneliness. In order to ensure emotional
wellbeing of the captive elephants, the
zookeepers and caregivers have spent
extended hours in the enclosures during the
lockdown period. This has posed a greater risk
for the zookeepers, as they have become more
prone to the TB infection from the elephants.
In 2015, the United States Department of
Agriculture (USDA) withdrew its policy
mandating the TB testing for captive
elephants in the USA, which earlier was an
integral part of the standard veterinary cares
for elephants. Subsequently, it has now been
left to the individual facilities (private, public,
or non-profit) and veterinarians to decide on
the testing. The regulations for the TB testing
of the elephants vary in terms of strictness
and requirements from one state to
another[15]. 
Clearly, the seriousness of the TB infection is
being ignored. The COVID-19 pandemic, and
the morbidity associated with it have shown
the world the level of price that we have to
pay due to our collective negligence. If
attention is not immediately paid to the finer
details associated with the critical diseases,
such as the various forms of TB, it would not
take a long time before another catastrophe is
witnessed. 
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The COVID-19 pandemic, and the morbidity
associated with it have shown the world the
level of price that we have to pay due to our
collective negligence. 
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